However, it has been shown that the reducing expression of SOX10 or the depletion of its target SAMMSON increases the sensitivity of BRAF-mutant melanoma to MAPK inhibitors, suggesting that upregulation of SOX10 promotes resistance to inhibitor therapy. The gene discussed is SOX10; the disease is melanoma.